BCL2 and type 2 diabetes mellitus: Results from the present study, after 30 days of treatment, indicate that SITG promoted anti-apoptosis capability by increasing Bcl-2 protein levels and protected the induction of apoptosis by reducing the Bax and Caspace-3 proteins levels in the brain tissues of T2DM-induced rats.